Its a great announcement. ill post it.
21 August, 2007
Company Announcement
Trust in Bioeffective® A leads to Visit by Director of Pasteur Institute
The Directors of Solagran Limited are pleased to announce that the Director of the Pasteur
Institute in St Petersburg, and Corresponding Member of the Russian Academy of Medical
Sciences, Professor Anatoly Zhebrun DSc, has accepted the Board’s invitation to visit
Australia to discuss recently completed trials in relation to the use of Bioeffective® A in the
prevention and treatment of Helicobacter Pylori infection, and at the same time establish a
joint platform for ongoing scientific co-operation and clinical trials.
The opportunity will also be taken to hold meetings with local clinicians and key figures from
the Australian medical establishment.
Professor Zhebrun is a world authority on infectious diseases with responsibility for Russia’s
disease control regime. Because of this role, any absence from Russia lasting more than four
days requires written permission from the Russian Minister for Health. His decision to devote
two weeks to this trip, and the Minister’s preparedness to permit such a long absence, is an
indication of the perceived value of the trip in the eyes of both men.
Professor Zhebrun has a particular scientific interest in H.Pylori – the bacterium associated
with stomach and duodenal ulcers, and other chronic conditions of the gastrointestinal tract.
The link between these conditions and H.Pylori infection was proven by the Australian
scientists Barry Marshall and Robin Warren. Their discovery is greatly appreciated in Russia.
Professor Zhebrun recently published a seminal text on H.Pylori entitled “Helicobacter Pylori
Infection”, citing 925 related articles. In his book, Professor Zhebrun makes the point that
H.Pylori is one of the most important infectious disease challenges confronting health
authorities worldwide. Not only is it the primary cause of stomach and duodenal ulcers, it is
also the cause of atrophic gastritis, and both cancer and lymphoma of the stomach. He also
points out that:
• 13 percent of all deaths from gastrointestinal conditions are related to H.Pylori infection,
and one in every 200 deaths worldwide is caused by stomach and duodenal ulcers.
• 70 out of every 100,000 people living in developed countries have a bleeding ulcer, with
the cost of treatment in each case being €2,000.
• Over the past 15 years, the incidence of stomach and duodenal ulcers and related
conditions has increased significantly among children up to 15 years of age in Russia.
• Gastritis related to H.Pylori does not have specific, easily identified symptoms, and this is
why the link to stomach cancer is not widely recognised. But H.Pylori infection increases
the risk of stomach cancer by between 6 and 18 times.
Worldwide, stomach cancer is the second most significant cause of death from cancer. World
Health Organisation figures show that it caused 801,000 deaths in 1999. Professor Zhebrun
argues strongly that the time for data gathering in relation to H.Pylori infection is past, and
the time has now come to act.
2
Under his personal supervision, the Pasteur Institute has recently completed a series of trials
to investigate the ability of Bioeffective® A to inhibit the growth and the reproduction of
H.Pylori. [Bioeffective® A is the name used in Russia, and within Solagran, for a substance
that is listed on the Australian Register of Therapeutic Goods as Conifer Green Needle
Complex.]
It is well known that H.Pylori infection is able to be treated effectively with a combination of
synthetic antibiotics. However, the work undertaken by Professor Zhebrun’s team from the
Pasteur Institute set out to determine:
• Firstly, the extent to which Bioeffective® A could provide an effective treatment with a
single natural product that exhibits none of the side effects associated with conventional
antibiotic therapy; and
• Secondly, whether it might also have the potential to prevent the spread of H.Pylori –
something which existing treatments simply cannot do.
H.Pylori is endemic in the population of many countries and is transmitted primarily via the
oral to oral route, including through the use of non-sterile eating utensils. It is estimated that
60 percent of the world’s population is infected, with up to 90 percent infected in some
countries. There is also an increased incidence of H.pylori infection in children in some
regions of Russia. While only a small proportion of those infected have clinic symptoms,
chronic infection still progresses and can lead to serious cases of stomach ulcer or cancer
many years after infection.
The prevalence of H.Pylori infection creates a real risk of re-infection for those that have
been treated with antibiotics. That is why measures to prevent infection and re-infection are
so important. Finding a way to prevent the spread of infection, as well as to treat infection
without the unpleasant side effects associated with existing treatments, would constitute a
clinical and epidemiological breakthrough of enormous magnitude. The commercial
consequences of such a breakthrough would be equally enormous.
Academician Zhebrun and his wife, Natalia Roshchina DSc (an eminent bio-physicist and
immuno-chemist) will be in Australia for twelve days from August 23. Solagran is pleased to
be associated with the Pasteur Institute, and it is honoured that Professor Zhebrun and Dr
Roshchina have agreed to travel to Australia at this time.
The Board believes that ongoing scientific co-operation between Solagran and the Pasteur
Institute, focussed on the prevention and treatment of infectious diseases, could lead to
significant benefits for both organisations.
Research conducted by Professor Zhebrun’s team, combined with work done by Professor
Vladimir Bespalov at the N.N. Petrov Institute of Oncology, has shown that Bioeffective® A
offers the potential to be used alone, or in combination with other therapies, to prevent and
treat both H.Pyori infection and the many diseases related to H.Pylori. Studies undertaken at
other leading Russian research institutions have also demonstrated the potential of a number
of different Bioeffectives® to be used to prevent and treat many infectious diseases. This
potential ranges from the ability of Bioeffective® R to enhance the body’s immune response
when confronted by viral pathogens, to the potential of Bioeffective® N to be used to
eliminate most forms of the Herpes virus. It also includes the ability of Bioeffective® A to
inhibit the growth and reproduction of a broad spectrum of pathogenic micro-organisms,
especially gram positive bacteria and including Methicillin-resistant Staphylococcus aureus
(MRSA) and other strains of Methicillin resistant bacteria, which was first identified by
scientists from the I.I. Mechnikov State Medical Academy in St Petersburg in 2006.
3
The Board of Solagran, and Professor Zhebrun, all believe that there is very real potential for
Solagran and the Pasteur Institute to work together in a way that can lead to significant
benefits for mankind – and for the people of Australia and Russia in particular.
Peter Stedwell
Company Secretary
On behalf of the Board of Directors
Solagran Limited
- Forums
- ASX - By Stock
- SLA
- h.pylori
h.pylori, page-2
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)